Chai D, Wang J, Fan C, Lim J, Wang X, Neeli P
J Hematol Oncol. 2024; 17(1):45.
PMID: 38886748
PMC: 11184848.
DOI: 10.1186/s13045-024-01566-1.
Chai D, Wang X, Neeli P, Zhou S, Yu X, Sabapathy K
Genes Dis. 2024; 11(4):100994.
PMID: 38560504
PMC: 10980946.
DOI: 10.1016/j.gendis.2023.04.027.
Wang Y, Hu S, Zhang W, Zhang B, Yang Z
Cell Death Discov. 2023; 9(1):433.
PMID: 38040675
PMC: 10692240.
DOI: 10.1038/s41420-023-01730-5.
Kanno K, Akutsu T, Ohdaira H, Suzuki Y, Urashima M
JAMA Netw Open. 2023; 6(8):e2328886.
PMID: 37606927
PMC: 10445201.
DOI: 10.1001/jamanetworkopen.2023.28886.
Casciano F, Zauli E, Busin M, Caruso L, AlMesfer S, Al-Swailem S
Cancers (Basel). 2023; 15(14).
PMID: 37509256
PMC: 10377487.
DOI: 10.3390/cancers15143593.
Autoantibodies as biomarkers for breast cancer diagnosis and prognosis.
Yang R, Han Y, Yi W, Long Q
Front Immunol. 2022; 13:1035402.
PMID: 36451832
PMC: 9701846.
DOI: 10.3389/fimmu.2022.1035402.
Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome.
Li S, Ma Y, Xiong Y, Zhang P, Wang X, Wang Y
Transl Cancer Res. 2022; 8(4):1364-1373.
PMID: 35116879
PMC: 8798311.
DOI: 10.21037/tcr.2019.07.25.
Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers.
Yang S, Liu C, Hong C, Huang Z, Wang H, Wei L
Dis Markers. 2021; 2021:5592693.
PMID: 34336006
PMC: 8289574.
DOI: 10.1155/2021/5592693.
Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma.
Li J, Qin B, Huang M, Ma Y, Li D, Li W
Front Immunol. 2021; 12:665106.
PMID: 33995397
PMC: 8119874.
DOI: 10.3389/fimmu.2021.665106.
Autoantibodies in Early Detection of Breast Cancer.
Rauf F, Anderson K, LaBaer J
Cancer Epidemiol Biomarkers Prev. 2020; 29(12):2475-2485.
PMID: 32994341
PMC: 7710604.
DOI: 10.1158/1055-9965.EPI-20-0331.
Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.
Acebes-Fernandez V, Landeria-Vinuela A, Juanes-Velasco P, Hernandez A, Otazo-Perez A, Manzano-Roman R
Nanomaterials (Basel). 2020; 10(7).
PMID: 32610601
PMC: 7407304.
DOI: 10.3390/nano10071274.
Mutant p53 as an Antigen in Cancer Immunotherapy.
Sobhani N, DAngelo A, Wang X, Young K, Generali D, Li Y
Int J Mol Sci. 2020; 21(11).
PMID: 32521648
PMC: 7312027.
DOI: 10.3390/ijms21114087.
P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.
Agupitan A, Neeson P, Williams S, Howitt J, Haupt S, Haupt Y
Int J Mol Sci. 2020; 21(10).
PMID: 32414156
PMC: 7278985.
DOI: 10.3390/ijms21103452.
Establishment and validation of an immunodiagnostic model for prediction of breast cancer.
Qiu C, Wang P, Wang B, Shi J, Wang X, Li T
Oncoimmunology. 2020; 9(1):1682382.
PMID: 32002291
PMC: 6959442.
DOI: 10.1080/2162402X.2019.1682382.
P53 and The Immune Response: 40 Years of Exploration-A Plan for the Future.
Levine A
Int J Mol Sci. 2020; 21(2).
PMID: 31952115
PMC: 7013403.
DOI: 10.3390/ijms21020541.
Understanding p53 functions through p53 antibodies.
Sabapathy K, Lane D
J Mol Cell Biol. 2019; 11(4):317-329.
PMID: 30907951
PMC: 6487784.
DOI: 10.1093/jmcb/mjz010.
Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.
Nabil G, Bhise K, Sau S, Atef M, El-Banna H, Iyer A
Drug Discov Today. 2018; 24(2):462-491.
PMID: 30121330
PMC: 6839688.
DOI: 10.1016/j.drudis.2018.08.009.
Autoimmunity and Gastric Cancer.
Bizzaro N, Antico A, Villalta D
Int J Mol Sci. 2018; 19(2).
PMID: 29373557
PMC: 5855599.
DOI: 10.3390/ijms19020377.
Putting p53 in Context.
Kastenhuber E, Lowe S
Cell. 2017; 170(6):1062-1078.
PMID: 28886379
PMC: 5743327.
DOI: 10.1016/j.cell.2017.08.028.
The mutational status of p53 can influence its recognition by human T-cells.
Shamalov K, Levy S, Horovitz-Fried M, Cohen C
Oncoimmunology. 2017; 6(4):e1285990.
PMID: 28507791
PMC: 5414872.
DOI: 10.1080/2162402X.2017.1285990.